Is Dr. Reddy's Laboratories Limited a good investment? Dr. Reddy's Laboratories Limited (DRREDDY.BO) is currently trading at 1376.00 INR. Market analysts have a consensus price target of 1313.16 INR. This suggests the asset is currently trading above analyst expectations.
In terms of valuation, the stock trades at a P/E ratio of 20.22. This valuation is generally in line with the broader market.
Earnings Schedule: Dr. Reddy's Laboratories Limited is expected to release its next earnings report on Jan. 22, 2027. The market consensus estimate for Forward EPS is 54.92.
For income investors, Dr. Reddy's Laboratories Limited pays a dividend yield of 0.65%. With a payout ratio of 12%, the dividend appears sustainable.
Yes, it pays an annual dividend of 8.00 INR (0.65% yield).
Dr. Reddy's Laboratories Limited is classified as a Stock. You can compare it against 2 other assets in the "Related Symbols" list on this page.
The next earnings date is projected to be Jan. 22, 2027. The company currently has a trailing EPS of 67.84.
Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company North America, Europe, India, Russia, and internationally. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segment. The Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business. The PSAI segment manufactures and markets active pharmaceutical ingredients and intermediates, which are principal ingredients for finished pharmaceutical products. This segment also provides contract research services; and manufactures and sells active pharmaceutical ingredients and steroids with the customer requirements. The Others segment engages in developing therapies in the fields of oncology and inflammation; and research and development of differentiated formulations. The company offers its products for various therapeutic categories, including gastro-intestinal, cardiovascular, anti-diabetic, dermatology, oncology, respiratory, stomatology, urology, and nephrology, vaccines and pain management. Dr. Reddy's Laboratories Limited was incorporated in 1984 and is headquartered in Hyderabad, India.
| Year | Total Dividends |
|---|---|
| ▸2027 |
8.00 INR
|
| July 7, 2027 (estimated) | 8.0000 |
| ▸2026 |
8.00 INR
|
| July 28, 2026 | 8.0000 |
| ▸2025 |
8.00 INR
|
| Aug. 23, 2025 | 8.0000 |
| ▸2024 |
40.00 INR
|
| Aug. 28, 2024 | 40.0000 |
| ▸2023 |
40.00 INR
|
| Aug. 26, 2023 | 40.0000 |
| ▸2022 |
30.00 INR
|
| Aug. 28, 2022 | 30.0000 |
| ▸2021 |
25.00 INR
|
| Aug. 27, 2021 | 25.0000 |
| ▸2020 |
25.00 INR
|
| Aug. 29, 2020 | 25.0000 |
| ▸2019 |
20.00 INR
|
| Aug. 29, 2019 | 20.0000 |
| ▸2018 |
20.00 INR
|
| Aug. 26, 2018 | 20.0000 |
| ▸2017 |
100.00 INR
|
| Aug. 27, 2017 | 100.0000 |
| ▸2016 |
100.00 INR
|
| July 18, 2016 | 100.0000 |
| ▸2015 |
100.00 INR
|
| July 10, 2015 | 100.0000 |
| ▸2014 |
90.00 INR
|
| July 11, 2014 | 90.0000 |
| ▸2013 |
75.00 INR
|
| July 12, 2013 | 75.0000 |
| ▸2012 |
68.75 INR
|
| June 28, 2012 | 68.7500 |
| ▸2011 |
56.25 INR
|
| June 30, 2011 | 56.2500 |
| ▸2010 |
56.25 INR
|
| July 2, 2010 | 56.2500 |
| ▸2009 |
31.25 INR
|
| July 3, 2009 | 31.2500 |
| ▸2008 |
18.75 INR
|
| July 4, 2008 | 18.7500 |
| ▸2007 |
18.75 INR
|
| July 6, 2007 | 18.7500 |
| ▸2006 |
50.00 INR
|
| July 7, 2006 | 50.0000 |
| ▸2005 |
50.00 INR
|
| July 7, 2005 | 50.0000 |
| ▸2004 |
50.00 INR
|
| July 13, 2004 | 50.0000 |
| ▸2003 |
50.00 INR
|
| Aug. 8, 2003 | 50.0000 |
| ▸2002 |
45.00 INR
|
| Aug. 8, 2002 | 25.0000 |
| March 8, 2002 | 20.0000 |
| ▸2001 |
130.00 INR
|
| Nov. 8, 2001 | 50.0000 |
| June 18, 2001 | 80.0000 |
| ▸2000 |
60.00 INR
|
| Sept. 7, 2000 | 10.0000 |
| April 4, 2000 | 50.0000 |
| Name | Payment Date | Status | Amount |
|---|---|---|---|
| Dr. Reddy's Laboratories Limited | Jul 28, 2026 | Paid | 8.0 INR |
Community Discussion